By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Synthetic Biologics, Inc. 

3930 Varsity Drive

Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-7800 Fax: 734-332-7878


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Synthetic Biologics (SYN) Release: Company Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA 1/19/2017 7:26:16 AM
Synthetic Biologics (SYN)' SYN-004 (Ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI) 1/5/2017 6:23:14 AM
Synthetic Biologics (SYN) Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough) 12/13/2016 6:15:04 AM
Synthetic Biologics (SYN) Announces Closing Of Public Offering Of Common Stock And Warrants 11/21/2016 7:21:34 AM
Synthetic Biologics (SYN) Announces Commencement Of Public Offering Of Common Stock And Warrants 11/15/2016 8:15:22 AM
Synthetic Biologics (SYN) Announces Pricing Of Public Offering Of Common Stock And Warrants 11/15/2016 7:42:42 AM
Synthetic Biologics (SYN) Reports Third Quarter 2016 Operational Highlights And Financial Results 11/1/2016 9:26:35 AM
Synthetic Biologics (SYN) To Report Third Quarter 2016 Operational Highlights And Financial Results On November 1, 2016 10/25/2016 9:30:13 AM
Synthetic Biologics (SYN) Awarded Research Contract From CDC For Microbiome Assessment And Intervention To Address Antibiotic Resistance 10/6/2016 7:13:57 AM
Synthetic Biologics (SYN) Announces Completion Of Enrollment For Phase 2b Proof-Of-Concept Clinical Trial For SYN-004 (Ribaxamase) For The Prevention Of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea And The Emergence Of Antibiotic-Resistant Organisms 9/20/2016 6:58:44 AM
12345678910...
//-->